Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

Annals of Hematology

Volumn 93, Issue 12, 2014, Pages 2037-2043

  Alvarez Larrán, Alberto ^a   Martínez Avilés, Luz ^b   Hernández Boluda, Juan Carlos ^c   Ferrer Marín, Francisca ^d   Antelo, María Luisa ^e   Burgaleta, Carmen ^f   Mata, M Isabel ^g   Xicoy, Blanca ^h   Martínez Trillos, Alejandra ⁱ   Gómez Casares, M Teresa ^j   Durán, M Antonia ^k   Marcote, Bárbara ^a   Ancochea, Agueda ^a   Senín, Alicia ^a   Angona, Anna ^a   Gómez, Montse ^c   Vicente, Vicente ^d   Cervantes, Francisco ⁱ   Bellosillo, Beatriz ^b   Besses, Carles ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e Universidad Pública de Navarra   (Spain)

^f HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^g HOSPITAL COSTA DEL SOL   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^k HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

more..

Author keywords

Busulfan; Essential thrombocythemia; Hematological response; Molecular response; Polycythemia vera

Indexed keywords

ALKYLATING AGENT; BUSULFAN; HYDROXYUREA; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

AGED; BLOOD CELL COUNT; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; DISEASE COURSE; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; GENETICS; HEMATOCRIT; HEMORRHAGE; HUMAN; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTICENTER STUDY; POLYCYTHEMIA VERA; REMISSION; RISK FACTOR; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALKYLATING AGENTS; BLOOD CELL COUNT; BUSULFAN; COMORBIDITY; DISEASE PROGRESSION; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; HEMATOCRIT; HEMORRHAGE; HUMANS; HYDROXYUREA; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; REMISSION INDUCTION; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; TREATMENT OUTCOME;

EID: 84922264206     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2152-7     Document Type: Article

References (24)

1. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, EuropeanLeukemiaNet (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–70
2. Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, Angona A, Amat P, Bellosillo B, Martínez-Avilés L, Navarro B, Teruel A, Martínez-Ruiz F, Besses C (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 152:81–8
3. Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119:1363–9
4. Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones AV, Cross NC, Silver RT (2013) JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica 98:e135–7
5. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092–7
6. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148:961–3
7. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T (2007) A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21:277–80
8. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ ctcaev3.pdf
9. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121:4778–81
10. Levine R, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, Gilliland DG, Busque L (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107:4139–41
11. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N (2007) The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 136:745–51
12. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemiavera who are refractory or intolerant to hydroxyurea. Cancer 120:513–20
13. Shvidel L, Sigler E, Haran M, Klepfish A, Duek A, Berrebi A, Shtalrid M (2007) Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia 21:2071–2
14. Brodsky I (1998) Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). Am J Clin Oncol 21:105–6
15. “Leukemia and Hematosarcoma” Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.) (1981) Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer 44:75–80
16. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G (1985) Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol 1985(61):657–66
17. D’Emilio A, Battista R, Dini E (1987) Treatment of primary proliferative polycythaemia by venesection and busulphan. Br J Haematol 65:121–2
18. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T, Investigators ECLAP (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664–70
19. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T (2000) Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 110:577–83
20. Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M, De Vivo A, Salmi F, Lucchesi A, Baccarani M, Vianelli N (2009) Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol 84:215–20
21. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005 Apr 1) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–32
22. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011 Oct 10) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29(29):3907–13
23. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012 Dec 20) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128–33, quiz 5252
24. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T (2008 Mar) GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3):372–80